Thu, Jul 24, 2014, 2:12 AM EDT - U.S. Markets open in 7 hrs 18 mins

Recent

% | $
Click the to save as a favorite.

Ironwood Pharmaceuticals, Inc. Message Board

  • equityvaluation equityvaluation May 6, 2010 10:47 PM Flag

    linaclotide data "very impressive."-Medpage story

    Here are some selected excerpts:

    NEW ORLEANS -- An investigational drug to relieve chronic constipation was effective and caused no unexpected safety issues in two phase III trials, researchers said here.
    Linaclotide, a chloride channel activator that boosts intestinal fluid secretion, significantly increased the number and quality of spontaneous bowel movements in patients who had been almost completely reliant on laxatives, according to Anthony Lembo, MD, of Beth Israel Deaconess Medical Center in Boston.
    Both trials "met their primary efficacy endpoint," he told attendees here at Digestive Disease Week, with significant improvement in every prespecified secondary endpoint compared with baseline and with placebo.

    The drug appeared to be almost immediately effective. At baseline, the mean weekly CSBM count was about 0.3, with 70% of patients having a count of zero. By week two, the mean in the active-treatment groups had risen to 2.5, whereas in the placebo group it was about 0.8.
    Spencer Dorn, MD, a gastroenterologist at the University of North Carolina in Chapel Hill, N.C., called the linaclotide data "very impressive."
    He said the drug would be "a welcome addition" to the sparse existing options for chronic constipation.
    Particularly appealing, Dorn said, was that linaclotide appeared to have faster onset than polyethylene glycol-based remedies and fewer side effects than more potent therapies.

    http://www.medpagetoday.com/MeetingCoverage/DDW/19946

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
IRWD
15.05+0.58(+4.01%)Jul 23 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.